---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-23-000045"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T06:22:57.333937+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MacroGenics sells TZIELD royalty to DRI for up to $200M; $100M upfront

## Summary
- Upfront payment of $100M for single-digit royalty on global net sales of TZIELD.
- MacroGenics retains a 50% share of royalty above an annual threshold.
- Eligible for up to $50M milestone tied to TZIELD advancement in newly diagnosed type 1 diabetes.
- Potential additional $50M if TZIELD achieves a specified net sales level.
- Closing expected March 15, 2023; MacroGenics keeps other regulatory and commercial milestones.

## SEC filing metadata
- accession: 0001125345-23-000045
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534523000045/0001125345-23-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534523000045/mgnx-20230308.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-23-000045
- JSON: https://secwatch.observer/filing/0001125345-23-000045.json
- Plain text: https://secwatch.observer/filing/0001125345-23-000045.txt

## Key facts
- Material Agreements
  MACROGENICS INC entered into Purchase and Sale Agreement with DRI Healthcare Acquisitions LP valued at $100 million (effective 2023-03-08).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: DRI Healthcare Acquisitions LP
  - Value: $100 million
  - Effective: 2023-03-08
  source text: On March 8, 2023 (the “Execution Date”), MacroGenics, Inc. (the “Company”) entered into a Purchase and Sale Agreement (the “Royalty Purchase Agreement”) with DRI Healthcare Acquisitions LP (“DRI”), a wholly owned subsidiary of DRI Healthcare Trust, for the sale to DRI of the Company’s single-digit royalty interest on global net sales of TZIELD (teplizumab-mzwv) (the “DRI Transaction”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1125345/000112534523000045/0001125345-23-000045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.